Cargando…

Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with an overall 5-year survival rate of 10%. Disease lethality is due to late diagnosis, early metastasis and resistance to therapy, including immunotherapy. PDA creates a robust fibroinflammatory tumor microenvironment that contributes t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmiechen, Zoe C., Stromnes, Ingunn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876239/ https://www.ncbi.nlm.nih.gov/pubmed/33584701 http://dx.doi.org/10.3389/fimmu.2020.613815

Ejemplares similares

Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma
por: Patterson, Michael T., et al.
Publicado: (2023)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
por: Burrack, Adam L., et al.
Publicado: (2019)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8(+) T cells in pancreatic cancer
por: Burrack, Adam L., et al.
Publicado: (2022)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
por: Li, Yan, et al.
Publicado: (2022)

Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins
por: Liot, Sophie, et al.
Publicado: (2021)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
por: Kabacaoglu, Derya, et al.
Publicado: (2018)

Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes
por: de Koning, Willem, et al.
Publicado: (2021)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
por: Sarantis, Panagiotis, et al.
Publicado: (2020)

The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis
por: Yang, Bing, et al.
Publicado: (2021)

Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity
por: Gonnermann, Daniel, et al.
Publicado: (2020)

5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma
por: Ebelt, Nancy D., et al.
Publicado: (2020)

Single-cell sequencing reveals heterogeneity between pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma with prognostic value
por: Zhang, Deyu, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
por: Foucher, Etienne D., et al.
Publicado: (2018)

Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma
por: Siret, Carole, et al.
Publicado: (2020)

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
por: de Santiago, Ines, et al.
Publicado: (2019)

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
por: Hou, Wanting, et al.
Publicado: (2022)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma
por: Kpeglo, Delanyo, et al.
Publicado: (2022)

Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
por: Hosen, S. M. Zahid, et al.
Publicado: (2022)

Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2022)

Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas
por: Zhuang, Hongkai, et al.
Publicado: (2021)

Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas
por: Huang, Yu, et al.
Publicado: (2022)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma
por: Huang, Can, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_91a3apd7kpra0aoi233rr7s3gb